Brainstorm Cell Therapeutics | BCLI - Operating Profit


Brainstorm Cell Therapeutics reported $-3.09M in Operating Profit for its fiscal quarter ending in March of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Biogen USD 659.6M 192.2M Sep/2025
Brainstorm Cell Therapeutics USD -3.09M 100K Mar/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -7.89M 540K Sep/2025
CSL USD 666M 1.31B Jun/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Grifols EUR 411.56M 15.51M Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Mesoblast USD -42.11M 21.69M Jun/2025